Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: A prospective study

BMJ Open

Volumn 4, Issue 7, 2014, Pages

  Stubendorff, Kajsa ^a,b   Larsson, Victoria ^a   Ballard, Clive ^c   Minthon, Lennart ^a   Aarsland, Dag ^d,e   Londos, Elisabet ^a  

^a LUND UNIVERSITY   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d STAVANGER UNIVERSITY HOSPITAL   (Norway)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; MEMANTINE; PLACEBO; ANTIPARKINSON AGENT;

AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION OF CHANGE SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PARKINSON DISEASE WITH DEMENTIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; COMPLICATION; LEWY BODY DISEASE; MORTALITY; MULTICENTER STUDY; SURVIVAL RATE;

AGED; ANTIPARKINSON AGENTS; DEMENTIA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MEMANTINE; PARKINSON DISEASE; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84903574358     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005158     Document Type: Article

References (24)

1. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007;68:812-19. (Pubitemid 46568532)
2. Aarsland D, Ballard CG, Halliday G. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004;17:137-45. (Pubitemid 39128223)
3. Ballard C, Kahn Z, Corbett A. Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Drugs Aging 2011;28:769-77.
4. Thomas SJ, Grossberg GT. Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging 2009;4:367-77.
5. Dalfo E, Albasanz JL, Martin M, et al. Abnormal metabotropic glutamate receptor expression and signaling in the cerebral cortex in diffuse Lewy body disease is associated with irregular alpha-synuclein/phospholipase C (PLCbeta1) interactions. Brain Pathol 2004;14:388-98. (Pubitemid 39524968)
6. Lipton SA. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2005;2:155-65. (Pubitemid 40862876)
7. Uitti RJ, Rajput AH, Ahlskog JE, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996;46:1551-6. (Pubitemid 26185770)
8. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009;8:613-18.
9. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:969-77.
10. Leroi I, Overshott R, Byrne EJ, et al. Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord 2009;24:1217-21.
11. Ondo WG, Shinawi L, Davidson A, et al. Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. Parkinsonism Relat Disord 2011;17:156-9.
12. Larsson V, Aarsland D, Ballard C, et al. The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. Int J Geriatr Psychiatry 2010;25:1030-8.
13. Larsson V, Engedal K, Aarsland D, et al. Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson's disease dementia. Dement Geriatr Cogn Disord 2011;32:227-34.
14. Jellinger KA, Wenning GK, Seppi K. Predictors of survival in dementia with lewy bodies and Parkinson dementia. Neurodegener Dis 2007;4:428-30. (Pubitemid 47557284)
15. Bostrom F, Hansson O, Blennow K, et al. Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2009;28:314-19.
16. Stubendorff K, Aarsland D, Minthon L, et al. The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson's disease with dementia. PLoS ONE 2012;7:e45451.
17. Gaig C, Valldeoriola F, Gelpi E, et al. Rapidly progressive diffuse Lewy body disease. Mov Disord 2011;26:1316-23.
18. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-72. (Pubitemid 43970103)
19. Johansson C, Ballard C, Hansson O, et al. Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. Int J Geriatr Psychiatry 2011;26:206-13.
20. Boersma F, Van Den Brink W, Deeg D, et al. Survival in a population-based cohort of dementia patients: predictors and causes of mortality. Int J Geriatr Psychiatry 1999;14:748-53. (Pubitemid 29450287)
21. Koopmans RT, van der Sterren KJ, van der Steen JT. The 'natural' endpoint of dementia: death from cachexia or dehydration following palliative care? Int J Geriatr Psychiatry 2007;22:350-5. (Pubitemid 46680846)
22. Albert SM, Sano M, Marder K, et al. Participation in clinical trials and long-term outcomes in Alzheimer's disease. Neurology 1997;49:38-43. (Pubitemid 27328679)
23. Schneider LS, Olin JT, Lyness SA, et al. Eligibility of Alzheimer's disease clinic patients for clinical trials. J Am Geriatr Soc 1997;45:923-8. (Pubitemid 27330120)
24. European Medicines Agency CfMPfHUC. Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias. London, 2008.